October 6, 2026
Title: Endpoints That Matter: Integrating Patient-Relevant Outcomes in HTA
Tuesday, October 6, 2026
11:00AM EDT | 3:00PM UTC | 5:00PM CEST
Click here for time zone conversion
Description
In oncology, evidence generation has long been anchored to established endpoints such as overall survival. These rarely capture the full breadth of benefit that technologies provide to patients. Disease control, functional capacity, health-related quality of life, and the ability to maintain daily life are not marginal concerns. They are central to how patients experience disease and evaluate therapeutic benefit. Yet these patient-relevant outcomes remain inconsistently identified and prioritized, and the endpoints intended to capture them are inadequately measured and insufficiently attributed in HTA submissions worldwide.
This webinar introduces a practical, four-stage framework for incorporating patient-relevant outcomes, and the endpoints that measure them, into the evidence generation and assessment of novel health technologies: 1. Identify What Matters, 2. Reconcile Priorities, 3. Measure Outcomes, and 4. Attribute Value. Starting with oncology, the framework is designed to help evidence generation teams embed patient-relevant endpoints into a medicine's development program from early clinical planning through HTA assessment.
Drawing on clinical, patient advocacy, and industry perspectives, the session will examine why alternative endpoints, meaning those used alongside or in place of established measures such as overall survival and selected because they capture intrinsic value relevant to patients or wider society, are necessary to a complete picture of therapeutic benefit. It will also address how patients and advocacy organizations define and prioritize outcomes that current trial designs often overlook, and how industry teams can identify and operationalize patient-relevant endpoint strategies.
Facilitated audience polls will surface real-world challenges and reinforce key learning points throughout the session.
By the end of this webinar, participants will be able to:
Explain why patient-relevant alternative endpoints are essential to robust HTA benefit assessment and not simply supportive evidence.
Apply a structured four-stage framework to identify, reconcile, measure, and communicate patient-relevant outcomes across an evidence development program.
Describe practical approaches used by clinical teams, patient organizations, and industry to integrate alternative endpoints into an evidence platform from early development to HTA submission.
Moderator:
Daniel Gladwell, PhD, Chief Scientific Officer, HEOR, Lumanity, Sheffield, United Kingdom
Speakers:
Ase Bratland, PhD, MD, Oslo University Hospital, Oslo, Norway
Antonella Cardone, MBA, CEO, Cancer Patients Europe, San Miniato, Italy
Jose Diaz, MSc, MD, Global HEOR - Health Systems Economics & Value of Innovation Lead, BMS, Uxbridge, United Kingdom
Sponsored by Corporate Partner, Lumanity.
Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar. Reservations are on a first-come, first-served basis.